培美曲塞联合顺铂一线治疗晚期非小细胞肺癌.docVIP

培美曲塞联合顺铂一线治疗晚期非小细胞肺癌【摘要】 目的 观察培美曲塞联合顺铂一线治疗晚期非小细胞肺癌的近期疗效及安全性。方法 对32例经病理组织学或细胞学检查确诊的晚期非小细胞肺癌初治患者进行培美曲塞联合顺铂化疗。培美曲塞500 mg/m2.,第1天静脉滴注;顺铂:75 mg/m2.,第1天静脉滴注,或顺铂30 mg/m2.,静脉滴注,连用3 d。每3周为1个周期重复,连用2~6个周期,进行疗效评价。结果 可评价32例病例中,无CR,PR11例,SD14例,PD7例。有效率为34.38%,疾病控制率为78.13%;临床受益反应率为71.88%。全组毒副反应较轻,主要为骨髓抑制及胃肠道反应,无治疗相关死亡。结论 培美曲塞联合顺铂一线治疗晚期非小细胞肺癌疗效肯定,毒副反应可以耐受,可推荐作为晚期非小细胞肺癌的规范一线治疗方法。 【关键词】 非小细胞肺癌;培美曲塞;化疗 Pemetrexed combined with cisplatin as first-line treatment in advanced non-small cell lung cancer WU Chu-rong,YANG Wen. Department of Oncology, Nanhai Hospital Affiliated to Southern Medical University, Foshan 528200, China 【Abstract】 Objective To explore the clinically efficacy and toxicity of pemetrexed combined cisplatin as first-line treatment in advanced non-small cell lung cancer (NSCLC). Methods A total of thirty-two chemotherapy-naive patients with stage IIIB or IV NSCLC were enrolled in this study and all of these patients had been confirmed with pathology or cytology. Patients received pemetrexed 500 mg/m2. on day 1 and cisplatin 75 mg/m2. on day 1 or 30 mg/m2. for three days. Every 3 weeks as one cycle.All patients who received 2 or more cycles could be evaluated. Results Thirty-two patients were evaluable for objective response, no CR,PR 11cases.SD 14 cases and PD 7 case.The response rate was 34.38%.The disease control rate was 78.13%. The clinical beneficial response rate was 71.88%.The common adverse effects were hematological toxicity and gastrointestinal response, and significantly lower.There was no coresponding death during treatment. Conclusion Treatment with pemetrexed combined cisplatin show good clinically efficacy,and with low side effects in the first-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for first-line NSCLC when available. 【Key words】 Non-small cell lung cancer;Peme trexed;Chemotherapy 肺癌是一种最常见的恶性肿瘤,其中非小细胞肺癌(Non-small cell lung cancer,NSCLC)占肺癌75%~80%,临床确诊时约2/3患者已处于中晚期阶段,丧失了根治性手